Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

477
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
477
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

429
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
429
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

491
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
491
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.1K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Dual-modal ultrasound-based deep learning radiomics for differentiation of benign and malignant breast lesions.

Gland surgery·2025
Same author

A narrative review on the applications of intracavitary contrast-enhanced ultrasonography in pediatric lower genitourinary anomalies.

Frontiers in pediatrics·2023
Same author

Hsa_circ_0002082 up-regulates Centromere Protein F via abolishing miR-508-3p to promote breast cancer progression.

Journal of clinical laboratory analysis·2022
Same author

γ-Aminobutyric Acid Suppresses Iron Transportation from Roots to Shoots in Rice Seedlings by Inducing Aerenchyma Formation.

International journal of molecular sciences·2020
Same author

The Hypoglycemic Effect of Berberine and Berberrubine Involves Modulation of Intestinal Farnesoid X Receptor Signaling Pathway and Inhibition of Hepatic Gluconeogenesis.

Drug metabolism and disposition: the biological fate of chemicals·2020
Same author

Enhanced Antimalarial Efficacy Obtained by Targeted Delivery of Artemisinin in Heparin-Coated Magnetic Hollow Mesoporous Nanoparticles.

ACS applied materials & interfaces·2020

相关实验视频

Updated: Mar 3, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.1K

人工智能在心力衰竭中的作用

Xueqin Li1, Yu Liu1, Xianya Zhang2

  • 1Department of Medical Ultrasound, Minda Hospital of Hubei Minzu University, Enshi, Hubei, China.

The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology
|March 1, 2026
PubMed
概括

人工智能 (AI) 正在改变心力衰竭 (HF) 的管理,超越"一刀切"的治疗方法. 这篇评论探讨了人工智能.

关键词:
人工智能的人工智能是人工智能.心脏衰竭是因为心脏衰竭.机器学习 机器学习患者管理 患者管理

更多相关视频

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

相关实验视频

Last Updated: Mar 3, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.1K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

科学领域:

  • 心血管医学和人工智能
  • 数字健康和精准医学数字健康和精准医学

背景情况:

  • 心力衰竭 (HF) 是一个日益严重的全球健康问题,影响着数百万人.
  • 当前的HF管理指南显示治疗疗效的变化,需要个性化方法.
  • 人工智能 (AI) 越来越多地被整合到心血管研究中,但对HF的临床翻译仍然有限.

研究的目的:

  • 在整个高频临床过程中对人工智能应用进行全面审查.
  • 分析AI在高频发展的前景和挑战.
  • 为未来临床转型和研究优化高频AI提供见解.

主要方法:

  • 对AI在高频患者诊断和亚型化中的应用进行系统审查.
  • 在预后评估和治疗反应预测中对AI的评估.
  • 对HF患者的治疗前后监测和远程护理中AI的评估.

主要成果:

  • 人工智能在各种高频管理阶段展示了潜力,从诊断到远程护理.
  • 具体的AI应用包括患者分层,风险预测和个性化治疗策略.
  • 该审查强调了人工智能在加强高风患者监测和远程护理方面的作用.

结论:

  • 人工智能为个性化HF护理提供了一个有希望的途径,解决了当前方法的局限性.
  • 人工智能的临床转化仍然存在挑战,需要进一步的研究和验证.
  • 未来的方向侧重于开发强大的AI系统,以无集成到临床实践中.